KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Payables: 2009-2024

Historic Payables for Ionis Pharmaceuticals (IONS) over the last 16 years, with Dec 2024 value amounting to $43.0 million.

  • Ionis Pharmaceuticals' Payables rose 58.26% to $14.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $97.5 million, marking a year-over-year increase of 69.93%. This contributed to the annual value of $43.0 million for FY2024, which is 65.07% up from last year.
  • Latest data reveals that Ionis Pharmaceuticals reported Payables of $43.0 million as of FY2024, which was up 65.07% from $26.0 million recorded in FY2023.
  • Ionis Pharmaceuticals' 5-year Payables high stood at $43.0 million for FY2024, and its period low was $11.9 million during FY2021.
  • For the 3-year period, Ionis Pharmaceuticals' Payables averaged around $29.0 million, with its median value being $26.0 million (2023).
  • In the last 5 years, Ionis Pharmaceuticals' Payables slumped by 30.79% in 2021 and then surged by 65.07% in 2024.
  • Ionis Pharmaceuticals' Payables (Yearly) stood at $17.2 million in 2020, then tumbled by 30.79% to $11.9 million in 2021, then soared by 50.55% to $17.9 million in 2022, then soared by 45.23% to $26.0 million in 2023, then skyrocketed by 65.07% to $43.0 million in 2024.